Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings.

Sharma, Kamal; Chandorkar, A B; Kovil, Rajiv; Venkataraman, S; Subrahmanyam, Kav; Mandal, Parthasarathi; Wasir, Jasjeet; Abhyankar, Mahesh; Prasad, Ashish; Sarda, Prashant S

Sharma, Kamal; Chandorkar, A B; Kovil, Rajiv; Venkataraman, S; Subrahmanyam, Kav; Mandal, Parthasarathi; Wasir, Jasjeet; Abhyankar, Mahesh; Prasad, Ashish; Sarda, Prashant S.

Afiliação

Sharma K; Department of Cardiology, Dr. Kamal Sharma Cardiology Clinic, Ahmedabad, IND.
Chandorkar AB; Department of Cardiology, Ruby Hall Clinic, Pune, IND.
Kovil R; Department of Diabetology and Endocrinology, Nanavati Super Specialty Hospital, Mumbai, IND.
Venkataraman S; Department of Diabetology, Soorya Hospital, Chennai, IND.
Subrahmanyam K; Department of Endocrinology, King George Hospital, Visakhapatnam, IND.
Mandal P; Department of Diabetes and Endocrinology, AMRI Hospitals, Kolkata, IND.
Wasir J; Department of Endocrinology, Medanta Hospital, Gurgaon, IND.
Abhyankar M; Scientific Services, USV Private Limited, Mumbai, IND.
Prasad A; Scientific Services, USV Private Limited, Mumbai, IND.
Sarda PS; Scientific Services, USV Private Limited, Mumbai, IND.

Cureus ; 13(11): e19194, 2021 Nov.

Article em En | MEDLINE | ID: mdl-34877189

Palavras-chave

cost effectiveness; cost-utility analysis; dapagliflozin; expert opinion; t2dm

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Cureus Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google